Overcoming multidrug-resistant lung cancer by mitochondrial-associated ATP inhibition using nanodrugs

Abstract

Despite the development of therapeutic modalities to treat cancer, multidrug resistance (MDR) and incomplete destruction of deeply embedded lung tumors remain long-standing problems responsible for tumor recurrence and low survival rates. Therefore, developing therapeutic approaches to treat MDR tumors is necessary. In this study, nanodrugs with enhanced intracellular drug internalization were identified by the covalent bonding of carbon nanotubes of a specific nano size and doxorubicin (DOX). In addition, carbon nanotube conjugated DOX (CNT-DOX) sustained in the intracellular environment in multidrug-resistant tumor cells for a long time causes mitochondrial damage, suppresses ATP production, and results in the effective therapeutic effect of drug-resistant tumors. This study identified that H69AR lung cancer cells, an adriamycin (DOX) drug-resistant tumor cell line, did not activate drug resistance function on designed nano-anticancer drugs with a specific nano size. In summary, this study identified that the specific size of the nanodrug in combination with DOX overcame multidrug-resistant tumors by inducing selective accumulation in tumor cells and inhibiting ATP by mitochondrial damage.

Alpha-hederin reprograms multi-miRNAs activity and overcome small extracellular vesicles-mediated paclitaxel resistance in NSCLC

“…Benzoxy-induced ROS enhanced ohitinib sensitivity by inhibiting the pSTAT3/SOCS3 and KEAP1/NRF2 pathways and promoting mitochondrial dysfunction ( Meng et al, 2023 ). Several multifunctional nanomaterials were used in combination with doxorubicin to overcome multidrug resistance by inducing selective accumulation and mitochondrial damage in tumor cells ( Park et al, 2023 ). In this and previous study, we explained that medicinal plant-derived small molecules shikonin and α-hederin overcome the resistance to cisplatin or paclitaxel in NSCLC cells ( Dai et al, 2022 ).…”

Nanodrug Delivery Systems for Myasthenia Gravis: Advances and Perspectives

“…Inevitably, mitochondria-targeting nanomaterials are widely employed in the treatment of cancer. The modification of nanocarriers with mitochondria-targeting moieties, such as novel TPP-based compounds [135] or ROS-responsive systems [136] can only inhibit drug resistance [137] but also induce a synergistic therapeutic effect [138]. These mitochondria-targeting nanomedicines shed light on potential drug design strategies for MG, which warrant deeper exploration.…”

Hollow MIL-125 Nanoparticles Loading Doxorubicin Prodrug and 3-Methyladenine for Reversal of Tumor Multidrug Resistance

“…Anticancer drugs, such as doxorubicin (DOX) and paclitaxel, are widely used to kill cancer cells in current clinical treatments, but cancer cells will develop a certain resistance to the drugs with the progression of time including a variety of anticancer drugs, which is called tumor multidrug resistance (MDR) [1][2][3][4]. MDR is a key factor in chemotherapy failure and tumor recurrence.…”